Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy (Q38606170)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

chronic liver disease

0 references

1 reference

Jose A Gonzalez-Gonzalez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jose A Gonzalez-Gonzalez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

Fernando Javier Lavalle-González

27 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

Jesús Zacarías Villarreal-Peréz

27 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Hector J Maldonado-Garza

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Diego García-Compeán

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Emmanuel Irineo González-Moreno

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

1 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

371-380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10620-015-3907-2

27 February 2020

exact match

0 references

cites work

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Diabetes increases the risk of acute hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Impact of diabetes on the severity of liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

New data and new concepts on the role of the liver in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Diagnosis and classification of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Insulin resistance and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Hepatitis C virus infection: evidence for an association with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Endocrine manifestations of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Hepatitis C virus infection and human pancreatic beta-cell dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Relationship of hepatitis C virus infection with diabetes in the U.S. population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

The relationship between hepatitis C virus infection and diabetes: time for a divorce?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Liver disease in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Clinical implications of hepatogenous diabetes in liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Abnormal glucose tolerance: a predictor of 30-day mortality in patients with decompensated liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Diabetes mellitus and decompensated cirrhosis: risk of hepatic encephalopathy in different age groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

The role of adipokines in liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Infections in Patients With End-stage Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Liver disease and diabetes: association, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Drug-induced hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Metformin-associated lactic acidosis: a rare or very rare clinical entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Metformin-associated lactic acidosis in a patient with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Drug-induced hypoglycaemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Gliclazide-induced acute hepatitis with hypersensitivity features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Repaglinide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Clinical pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Dipeptidyl peptidase-4: a key player in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3907-2

Hepatogenous diabetes in cirrhosis: academic sport or a neglected disease?

21 January 2018

1 reference

12 December 2020

Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation

1 reference

12 December 2020

Prognostic significance of diabetes in patients with cirrhosis

1 reference

12 December 2020

Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis

1 reference

12 December 2020

Liver fibrogenesis and metabolic factors

1 reference

12 December 2020

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

1 reference

12 December 2020

Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis

1 reference

12 December 2020

Impact of diabetes mellitus on outcome of HCC.

1 reference

12 December 2020

Alterations of glucose metabolism in chronic liver disease

1 reference

12 December 2020

Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study

1 reference

12 December 2020

Plasma cytokine levels imbalance in cirrhotic patients with impaired glucose tolerance and diabetes mellitus. A prospective study.

1 reference

12 December 2020

Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.

1 reference

12 December 2020

Clinical Manifestations and Treatment Options in Patients with Cirrhosis and Diabetes Mellitus

1 reference

12 December 2020

Association between hepatitis C, diabetes mellitus, and race. a case-control study

1 reference

12 December 2020

Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria

1 reference

12 December 2020

Long-term survival in patients with hereditary hemochromatosis

1 reference

12 December 2020

Cardiovascular disease in cirrhosis--a point-prevalence study in relation to glucose tolerance

1 reference

12 December 2020

Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events

1 reference

12 December 2020

The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US

1 reference

12 December 2020

The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study.

1 reference

12 December 2020

The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study.

1 reference

12 December 2020

Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis

1 reference

12 December 2020

Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients.

1 reference

12 December 2020

[Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis]

1 reference

12 December 2020

10.1007/S10620-015-3907-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462490%20AND%20SRC:MED&resulttype=core&format=json